Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Yumie TakeshitaMasao HondaKenichi HaradaYuki KitaNoboru TakataHiromasa TsujiguchiTakeo TanakaHisanori GotoYujiro NakanoNoriho IidaKuniaki AraiTatsuya YamashitaEishiro MizukoshiHiroyuki NakamuraShuichi KanekoToshinari TakamuraPublished in: Diabetes care (2022)
Tofogliflozin and, to a lesser degree, glimepiride led to liver histological and metabolic improvement in participants with type 2 diabetes and NAFLD, with no significant difference between the agents. The hepatic expression of the genes involved in energy metabolism, inflammation, and fibrosis was well correlated with liver histological changes and rescued by tofogliflozin. We need further confirmation through long-term larger-scale clinical trials of SGLT2 inhibitors.